


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450 on October 20, 2004.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT  
Examining Group 1634  
Patent Application  
Docket No. INN-113T  
Serial No. 09/529,759

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Bradley L. Sisson  
Art Unit : 1634  
Applicant(s) : Full names of inventors  
Serial No. : 09/529,759  
Filed : April 18, 2000  
Conf. No. : 9965  
For : Documentation Means for Repertoires of NKR Immunoreceptors and/or  
Activatory or Non-Inhibitory Immunoreceptor Counterparts of NKR  
Immunoreceptors

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Sir:


In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/ssA

Attachments: Form PTO/SB/08 (1 page)  
Copies of references cited



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1992, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/529,759
Filing Date	April 18, 2000
First Named Inventor	Eric Vivier
Group Art Unit	1634
Examiner Name	Bradley L. Sisson
Attorney Docket Number	INN-113T

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	GeneCard database printout for GenBank Accession No: U24076, pp1-7 (for Human Gene Nomenclature database symbol KIR2DL1 (killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1)	
	R2	CANTONI, C. <i>et al.</i> (1996) "Molecular structures of HLA-specific human NK cell receptors" IN: Moretta, L (ed): <i>Molecular Basis of NK Cell Recognition and Function</i> . <i>Chem Immunol.</i> 64:88-103.	
	R3	ALBI, N. <i>et al.</i> (1996) "Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "Three-Loci" HLA-incompatible bone marrow transplantation" <i>Blood</i> 87(9):3993-4000.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.